HOME >> MEDICINE >> NEWS
Study shows use of budesonide reduced the risk of asthma related events by 40% in children

San Antonio, Tex., - March 19, 2005 New data indicated that earlier intervention with once-daily budesonide, an inhaled corticosteroid delivered by dry powder inhaler to children with mild persistent asthma, significantly reduced the long-term risk and frequency of severe asthma-related events as well as the need for other inhaled medication.

The findings, presented today at the 61st annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI), are from two analyses of the Inhaled Steroid as Regular Therapy in Early Asthma (START) study, a three-year trial involving nearly 2,000 children aged 5 to 10 years with mild persistent asthma. The START study was funded by AstraZeneca.

"Many children with asthma make repeated trips to the emergency room or are hospitalized because of worsening symptoms," said Dr. Albert Sheffer, Clinical Professor of Medicine at Harvard Medical School, Director Emeritus at the Allergy Clinic, Brigham and Women's Hospital in Boston and an investigator in the safety and tolerability portion of the study. "The findings of these two analyses showed that budesonide had a viable long-term treatment effect."

In the first analysis, 1,974 children were randomized to receive either once-daily budesonide or placebo in addition to usual asthma care. The earlier use of budesonide reduced the risk of exacerbation, or severe asthma related events by 40 percent compared to usual asthma care. In addition, children in the budesonide group required fewer interventions with other inhaled corticosteroids (12.3 percent versus 22.7 percent for placebo), and had improved lung function.

The second analysis tracked the adverse side effects reported by 1,981 children taking either budesonide plus usual care or placebo over three years. Overall, the incidence of side effects was comparable between the two groups, with fewer asthma exacerbations and adverse events reported in the budesonide group throughout
'"/>

Contact: Heather Law
heather.law@astrazeneca.com
302-886-1652
Burson-Marsteller
21-Mar-2005


Page: 1 2 3

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
10. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women
11. Study of obese diabetics explains why low-carb diets produce fast results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... practice partnerships through affiliations and de novo development, today announced Cumberland Skin ... , Cumberland Skin Surgery and Dermatology, with offices in both Hermitage and Lebanon, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The ... a three-year grant totaling $975,000, renewing its funding from the Health Resources and ... , This funding marks, the fourth time the HRSA administration has renewed its ...
(Date:8/16/2017)... ... , ... A global leader in the treatment of clubfoot, CURE International ... states—bringing the country one step closer to eliminating clubfoot as a lifelong disability by ... track to enroll 10,000 children in the clubfoot treatment program in this year alone. ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s ... Economist Intelligence Unit’s (EIU) annual Liveability Index. , The Index surveys 140 of the ... began in 2006, Melbourne has consistently come in the top three of the index. ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... $5.99, eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery ... of God's love, and all the many ways God shows love to those ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: ... second-quarter 2017 and updated financial guidance for the full-year ... Highlights Reported net sales of $397.6 ... quarter. Net sales at constant currency (organic) grew by ... $0.51, compared to $0.60 in the prior-year quarter. Second-quarter ...
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
(Date:7/25/2017)... LAUDERDALE, Fla. , July 25, 2017  Debbie,s Dream Foundation: Curing Stomach ... Luncheon on Monday, September 25, 2017 at the Bonaventure Resort & Spa in ... ... Gendler, DDF Founder and President Debbie Zelman, and Luncheon Committee Co-chair Sabrina Kurzman. ... ...
Breaking Medicine Technology:
Cached News: